Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025GlobeNewsWire • Tuesday
Why Fast-paced Mover Theratechnologies (THTX) Is a Great Choice for Value InvestorsZacks Investment Research • 08/01/24
Despite Fast-paced Momentum, Theratechnologies (THTX) Is Still a Bargain StockZacks Investment Research • 07/16/24
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024GlobeNewsWire • 07/10/24
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business UpdateGlobeNewsWire • 06/26/24
Theratechnologies (THTX) Is Attractively Priced Despite Fast-paced MomentumZacks Investment Research • 06/05/24
Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid TumorsGlobeNewsWire • 05/23/24
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO MeetingGlobeNewsWire • 05/02/24
Theratechnologies (THTX) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 04/23/24
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of ShareholdersGlobeNewsWire • 04/15/24
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceGlobeNewsWire • 04/11/24
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024GlobeNewsWire • 04/10/24
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology PlatformGlobeNewsWire • 04/08/24
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business UpdateGlobeNewsWire • 04/03/24
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ PlatformGlobeNewsWire • 03/28/24
Theratechnologies Announces Update on its Preclinical Oncology Research ProgramGlobeNewsWire • 03/22/24
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerGlobeNewsWire • 03/21/24
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain TrudeauGlobeNewsWire • 02/29/24
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDAGlobeNewsWire • 02/27/24